Business Context and Reporting Period
This Form 8-K filing by Arvinas, Inc. (ARVN) reports a significant change in executive leadership and board composition. The report date is February 10, 2026, with the effective date of the changes being February 12, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation and severance arrangements.
- New CEO Base Salary: $680,000 annually.
- New CEO Bonus Target: 60% of base salary.
- New CEO Equity Grant: 218,691 stock options and 147,179 restricted stock units (RSUs).
- Outgoing CEO (Dr. Houston) Compensation: $457,000 lump sum (2025 bonus equivalent) and $27,914.40 for 12 months of health coverage premiums.
Material Changes Versus Prior Period
The primary material change is the departure of John Houston, Ph.D., as President, CEO, and Chair of the Board, and the appointment of Randy Teel, Ph.D., to those roles.
- Leadership Transition: Dr. Houston resigns effective February 12, 2026, but remains on the Board and transitions to a consultancy role through March 1, 2027.
- Board Composition: Briggs Morrison, M.D., is appointed Chair of the Board. Randy Teel, Ph.D., is appointed to the Board alongside his executive roles.
- Internal Promotion: Dr. Teel, previously Chief Business Officer (since April 2024) and interim CFO (Feb-June 2024), is promoted to CEO.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of operational risks. It details the terms of the new employment agreement and the consulting agreement, including severance provisions.
- Severance Terms (Dr. Teel):
- Without Cause/Good Reason (Standard): 12 months of base salary and health coverage.
- Without Cause/Good Reason (Post-Change in Control): 18 months of base salary, 18 months of health coverage, 150% of target bonus, and full acceleration of unvested equity.
- Consulting Terms (Dr. Houston): Includes a fixed bonus equivalent, health premium reimbursement, and continued equity vesting.
Investor Verification Checklist
- Verify the stock price on the grant date to calculate the total value of Dr. Teel's option grant.
- Review the definition of "Change in Control" in the employment agreement to understand the trigger for enhanced severance.
- Confirm the status of the search for a permanent CFO, as Dr. Teel previously served in an interim capacity.
- Monitor the transition plan for Dr. Houston's consultancy role to ensure continuity of strategic initiatives.